HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wildcard President Trump And The Prospects For Cosmetics Reg Reform

This article was originally published in The Rose Sheet

Executive Summary

EWG maintains that “the result of the election has no effect whatsoever on the need for cosmetics reform,” but it remains to be seen how legislative proposals for increased oversight would be received by the president-elect, who has outlined plans for dramatically cutting perceived overregulation. Meanwhile, new leadership is likely to be appointed at FDA, and hopes dwindle regarding the Trans-Pacific Partnership.

You may also be interested in...



Cosmetics Reg Reform Ill-Situated As Trump, FDA Explore 'Burden Reduction'

Any movement to advance proposed cosmetics reform legislation could be seen as running counter to President Trump's executive orders earlier this year, which now have FDA centers seeking "broad public comment" on how to achieve "meaningful burden reduction."

ICMAD: Small Business Looks To Pull Off Preemption Balancing Act

National uniformity in cosmetics regulation remains a top legislative priority for the Independent Cosmetic Manufacturers and Distributors. At the same time, the small business trade association acknowledges that compromise will likely be needed to balance state rights with the streamlined certainty that a strong national standard would provide for industry.

Pallone Proposes House Companion To PCPSA; Will 2017 Be The Year For Reform?

Like the Personal Care Products Safety Act in the Senate, a bipartisan discussion draft from New Jersey congressmen Frank Pallone and Leonard Lance would require registration and fees from industry while giving FDA ingredient-review duties and recall authority. 2017 could be the year that cosmetics reform legislation goes the distance, but first the Senate will be holding a related hearing September 22.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108681

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel